BDX · 10-Q · 2026Q2

BECTON DICKINSON & CO

Filed 2026-08-06 · Healthcare · View original filing on EDGAR

Ranked Events

• Capital Return ProgramImportance 83 · Surprise 82
  BD paid $875 million of cash dividends to common shareholders during the first nine months of fiscal 2026. BD repurchased approximately $2.250 billion of common stock during the same period, compared with $750 million…
• Acquisition / Partnership / DivestitureImportance 71 · Surprise 60
  On February 9, 2026, BD completed the spin-off of its former Biosciences and Diagnostic Solutions business and its combination with Waters Corporation in a Reverse Morris Trust transaction. The former Life Sciences…
• Liquidity and Debt PositionImportance 66 · Surprise 40
  At June 30, 2026, BD held $864 million of cash, equivalents and short-term investments, including restricted cash. Total debt declined to $16.808 billion from $19.180 billion at September 30, 2025, and debt as a…
• Headcount / RestructuringImportance 58 · Surprise 42
  BD recorded $450 million of non-cash asset impairment charges in the first nine months of fiscal 2026. The charges followed a commitment to exit operational activities and projects that no longer align with the…
• Income Tax Rate ChangesImportance 50 · Surprise 58
  The nine-month effective tax rate for continuing operations increased to 19.8% in fiscal 2026 from 16.7% in fiscal 2025. The increase reflected recognition of a deferred tax liability after BD decided to distribute…
• Geographic Market CommentaryImportance 49 · Surprise 32
  U.S. third-quarter revenue grew 6.9%, with strong sales across Medical Essentials, Connected Care Medication Management Solutions, BioPharma Systems, and Interventional Peripheral Intervention and Urology and Critical…
• Revenue Performance and MixImportance 49 · Surprise 32
  Third-quarter worldwide revenue increased 5.4%, with volume and other factors contributing 4.1 percentage points. Connected Care benefited from a strong backlog of customer orders in Medication Management Solutions,…
• Segment Revenue PerformanceImportance 49 · Surprise 32
  Third-quarter revenue increased 4.5% in Medical Essentials to $1.675 billion, 4.9% in Connected Care to $1.224 billion, and 6.4% in Interventional to $1.414 billion. BioPharma Systems revenue increased 6.6%, driven by…
• Gross Margin DriversImportance 45 · Surprise 50
  Third-quarter gross margin declined to 46.4% from 47.3% a year earlier, a 90-basis-point decrease. Operating performance reduced the quarterly margin by 0.8 percentage points, primarily because of tariffs, higher labor…
• FDA El Paso Warning LetterImportance 44 · Surprise 60
  On April 30, 2026, BD’s El Paso manufacturing facility received a Warning Letter from the FDA’s Center for Drug Evaluation and Research following an October 2025 inspection of drug-device combination products,…
• Capital ExpendituresImportance 42 · Surprise 14
  BD invested $376 million in capital expenditures during the first nine months of fiscal 2026, compared with $383 million in the prior-year period. The capital program focused on projects that improve the cost…
• Ethylene Oxide RegulationImportance 40 · Surprise 42
  The EPA and state environmental regulators are increasing scrutiny of ethylene oxide emissions, which could require BD or its sterilization providers to install controls, limit usage, suspend operations, or incur…
• Ethylene Oxide CostsImportance 40 · Surprise 42
  BD’s ethylene oxide sterilization facilities received a two-year Presidential compliance exemption from the EPA’s revised NESHAP requirements, but BD continues implementing facility changes and new emissions-control…
• Regulatory Approval MilestonesImportance 40 · Surprise 42
  BD remains subject to an amended FDA consent decree governing its U.S. infusion-pump operations, with the FDA continuing to review observations from a 2024 Form 483 and the company’s corrective action plan. The decree…
• Trade Policy and TariffsImportance 40 · Surprise 42
  Tariffs, sanctions and other trade barriers imposed by or against the United States adversely affected BD’s third-quarter fiscal 2026 operating expense and are expected to continue affecting fiscal 2026 and potentially…
• Ethylene Oxide Sterilization CapacityImportance 37 · Surprise 42
  Ethylene oxide remains the most frequently used sterilant for U.S. medical devices and healthcare products and, in some cases, the only available option for critical products. New emissions and pesticide-use…
• Supply Chain ConstraintsImportance 37 · Surprise 42
  BD said major disruptions in sourcing, manufacturing or distribution could affect product availability and results. The Middle East conflict had not significantly affected global supply or distribution as of the…
• Product Launch and TransitionImportance 34 · Surprise 42
  BD’s updated BD Alaris Infusion System received FDA 510(k) clearance in July 2023, supporting remediation and the system’s return to the U.S. market. The clearance includes updated hardware for PCU, large-volume,…
• Operating Expense TrendsImportance 31 · Surprise 32
  Selling and administrative expense increased to $1.261 billion in the third quarter from $1.163 billion, and to $3.703 billion for the first nine months from $3.435 billion. Selling and administrative expense…
• China Healthcare Cost ControlsImportance 29 · Surprise 24
  BD reported adverse effects from China market dynamics, including volume-based procurement programs (VoBP) and government efforts to contain healthcare costs and improve healthcare-practitioner compliance. These…

Revenue by Product (in millions)

Revenue by Geography (in millions)